926 811

Cited 0 times in

재발성/불응성 소아 급성림프모구백혈병 환자의 치료 경향 및 성적에 대한 다기관 후향적 관찰 연구

DC Field Value Language
dc.contributor.author유철주-
dc.date.accessioned2018-07-20T11:54:14Z-
dc.date.available2018-07-20T11:54:14Z-
dc.date.issued2017-
dc.identifier.issn2233-5250-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/161473-
dc.description.abstractBackground: Although the overall survival of childhood acute lymphoblastic leukemia (ALL) approaches 85-90%, the prognosis of relapsed or refractory (R/R) ALL is grave. This study aimed to identify the treatment pattern, treatment response, and overall survival of these patients.Methods: We reviewed data of 64 patients with R/R ALL whose initial diagnosis of ALL had been made between 1 and 21 years of age. Patients who received clofarabine as part of an induction regimen were excluded. Relapsed patients were limited to those who relapsed after ≥2 prior induction regimens. Treatment patterns, response rates, and overall survival were analyzed.Results: Patients’ median age was 15.0 years (range, 6.0-25.0) at the diagnosis of R/R ALL. The most frequently used agents other than steroid were vincristine (54.0%), cytarabine (44.6%), and idarubicin (36.5%), while L-asparaginase was used in only one patient. The complete remission (CR) and overall response (OR) rates were 38.1 and 42.9%, respectively. Sixteen patients (25.4%) underwent allogeneic hematopoietic stem cell transplantation (HSCT). The 5-year overall survival was 6.7%. The survival of patients with HSCT was significantly higher compared with those without HSCT (35.2% vs 0%, P=0.0097). Among 14 patients who achieved CR or CR without platelet recovery (CRp) before HSCT, the 3-year survival was 46.9%. Conclusion: The survival of Korean patients with R/R childhood ALL was dismal despite a reasonable CR rate, whereas that of those who received HSCT after CR or CRp was excellent. More treatment options are needed to improve the overall outcome of R/R childhood ALL.-
dc.description.statementOfResponsibilityopen-
dc.languageKorean-
dc.publisherClinical Pediatric Hematology-Oncology-
dc.relation.isPartOfClinical Pediatric Hematology-Oncology-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.title재발성/불응성 소아 급성림프모구백혈병 환자의 치료 경향 및 성적에 대한 다기관 후향적 관찰 연구-
dc.title.alternativeA Multicenter Retrospective Analysis on the Treatment Pattern and Outcome in Relapsed/Refractory Childhood Acute Lymphoblastic Leukemia-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Pediatrics-
dc.contributor.googleauthorKeon Hee Yoo-
dc.contributor.googleauthorNak Gyun Chung-
dc.contributor.googleauthorBin Cho-
dc.contributor.googleauthorHyoung Jin Kang-
dc.contributor.googleauthorHee Young Shin-
dc.contributor.googleauthorHo Joon Im-
dc.contributor.googleauthorJong Jin Seo-
dc.contributor.googleauthorYoung Tak Lim-
dc.contributor.googleauthorChuhl Joo Lyu-
dc.contributor.googleauthorSoon Ki Kim-
dc.contributor.googleauthorIn-Sang Jeon-
dc.contributor.googleauthorHoon Kook-
dc.contributor.googleauthorHong Hoe Koo-
dc.identifier.doi10.15264/cpho.2017.24.2.101-
dc.contributor.localIdA02524-
dc.relation.journalcodeJ00605-
dc.subject.keywordChildhood-
dc.subject.keywordAcute lymphoblastic leukemia-
dc.subject.keywordRelapsed-
dc.subject.keywordRefractory-
dc.contributor.alternativeNameLyu, Chuhl Joo-
dc.contributor.affiliatedAuthorLyu, Chuhl Joo-
dc.citation.volume24-
dc.citation.number2-
dc.citation.startPage101-
dc.citation.endPage106-
dc.identifier.bibliographicCitationClinical Pediatric Hematology-Oncology, Vol.24(2) : 101-106, 2017-
dc.identifier.rimsid61381-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.